Korsana emerges with $175m to combat neurodegenerative diseases
US biotech Korsana Biosciences has emerged from stealth with $175 million in funding and a focus on developing next-generation biologics designed to reach the brain more effectively and improve the treatment of neurodegenerative diseases. The Waltham, Massachusetts-based company is the sixth biotech to emerge from the...
Why it mattersThis financing signal shows where investor conviction is concentrating and which longevity business models are most likely to secure future capital.